Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989 | 1.00 | KDM4E (0.70) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL4538345 | 0.98 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| Acetic Acid SCHEMBL28860398 | 0.94 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| Acetamide SCHEMBL28213479 | 0.90 | KDM4E (0.57) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL28905979 | 0.89 | KDM4E (0.55) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL17258354 | 0.88 | KDM4E (0.59) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL960010 | 0.84 | ALDH1A1 (0.51) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL720696 | 0.83 | KDM4E (1.00) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL34595 | 0.83 | KDM4E (1.00) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL13932169 | 0.82 | KDM4E (0.50) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| CN-118480001-A | C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof | 贵州省天然产物研究中心 | 2024-08-13 | — | — | CN | disclosed |
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-115557929-A | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-109715612-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2022166796-A1 | PYRIMIDINE OR PYRIDINE AND HETEROCYCLIC ADENOSINE RECEPTOR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | KDM4E 1423/4885ALOX15 1323/4885TSHR 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.